GlassScriptPhysician profile
Gary A Barkocy
NPI 1114931573
$6,001.05
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $626 · 2021: $1,105 · 2022: $1,120 · 2023: $1,384 · 2024: $763 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,233.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $908.93 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $526.39 | 2021-2025 | Lifevest |
| Abiomed | $503.89 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $443.58 | 2021-2025 | Verquvo |
| Pfizer INC. | $432.37 | 2019-2025 | |
| Medtronic, INC. | $284.06 | 2022-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $280.78 | 2019-2024 | Watchman, Watchman Flx |
| Janssen Pharmaceuticals, INC | $270.73 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $237.90 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.91 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $177.03 | 2020-2024 | |
| Abbott Laboratories | $168.32 | 2024-2025 | Jot Dx, Assurity, Perclose Prostyle |
| Shockwave Medical, INC | $61.88 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Digirad Health, INC | $54.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $42.19 | 2020-2022 | |
| Medtronic Vascular, INC. | $39.61 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.95 | 2020 | |
| Bolton Medical INC | $21.43 | 2023 | Treo Abdominal Stent-Graft System |
| Alnylam Pharmaceuticals INC. | $18.74 | 2021 | |
| Allergan, INC. | $17.09 | 2019 | |
| Amgen INC. | $16.44 | 2021 | |
| Gilead Sciences, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Barkocy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.